Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma

Next Previous
Trial Profile

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Panobinostat (Primary) ; Busulfan; Dexamethasone; Gemcitabine; Glutamine; Melphalan; Palifermin; Pyridoxine; Pyridoxine
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 29 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020.
    • 29 Jan 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
    • 15 Sep 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top